Research Article| Volume 43, ISSUE 4, P801-807, April 2017

Download started.


Timing of initiation of adjuvant chemotherapy for gastric cancer: A case-matched comparison study of laparoscopic vs. open surgery

Published:January 29, 2017DOI:



      Laparoscopic gastrectomy (LG) is reported to be associated with faster recovery than open gastrectomy (OG); however, the influence of the surgical approach on initiation timing of adjuvant chemotherapy (AC) remains unclear.


      This was a single-institutional retrospective observational study. Patients with pathological stage II/III gastric cancer undergoing LG with D2 lymphadenectomy (LG group: n = 74) were matched 1:1 with patients selected from 214 similar patients undergoing OG (OG group: n = 74), identically matching gender, age, pathological stage, and type of gastrectomy, and comparing AC initiation timing between the two groups. Factors associated with delayed initiation of AC were investigated in a multivariable analysis.


      AC was performed in 86.5% (LG) and 83.8% (OG) of patients (p = 0.64). The median time interval before AC was significantly shorter in the LG vs. OG group (5.7 vs. 6.6 weeks, respectively, p < 0.001), and significantly more patients received AC within 6 weeks (60.8% vs. 27.0%, p < 0.001). Independent factors associated with delayed initiation of AC (>6 weeks) were: morbidity (≥grade 3a; odds ratio (OR): 16.1, 95% confidence interval (CI): 1.86–143), open surgery (OR: 5.17, 95% CI: 2.50–13.1), and postoperative weight loss ≥ 8% (OR: 2.47, 95% CI: 1.07–5.71).


      LG may be associated with shorter intervals before AC. Postoperative morbidity should be reduced as much as possible.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ferlay J.S.I.
        • Ervik M.
        • Dikshit R.
        • Eser S.
        • Mathers C ea
        GLOBOCAN 2012 v1.0. Cancer Incidence MortalityWorldwide.
        IARC CancerBase. 2012; (2012. [accessed May 15, 2015])
        • Songun I.
        • Putter H.
        • Kranenbarg E.M.
        • Sasako M.
        • van de Velde C.J.
        Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.
        Lancet Oncol. 2010; 11: 439-449
        • Sakuramoto S.
        • Sasako M.
        • Yamaguchi T.
        • et al.
        Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
        N Engl J Med. 2007; 357: 1810-1820
        • Bang Y.J.
        • Kim Y.W.
        • Yang H.K.
        • et al.
        Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
        Lancet. 2012; 379: 315-321
        • Tewari K.S.
        • Java J.J.
        • Eskander R.N.
        • Monk B.J.
        • Burger R.A.
        Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group studydagger.
        Ann Oncol. 2016; 27: 114-121
        • Des Guetz G.
        • Nicolas P.
        • Perret G.Y.
        • Morere J.F.
        • Uzzan B.
        Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis.
        Eur J Cancer. 2010; 46: 1049-1055
        • Biagi J.J.
        • Raphael M.J.
        • Mackillop W.J.
        • Kong W.
        • King W.D.
        • Booth C.M.
        Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis.
        JAMA. 2011; 305: 2335-2342
        • Japanese Gastric Cancer Association
        Japanese gastric cancer treatment guidelines 2014 (ver.4).
        Gastric Cancer. 2017; 20: 1-19
        • Park H.S.
        • Jung M.
        • Kim H.S.
        • et al.
        Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer.
        Ann Surg Oncol. 2015; 22: 224-231
        • Yamamoto M.
        • Sakaguchi Y.
        • Kinjo N.
        • et al.
        S-1 adjuvant chemotherapy earlier after surgery clinically correlates with prognostic factors for advanced gastric cancer.
        Ann Surg Oncol. 2016; 23: 546-551
        • Kitano S.
        • Iso Y.
        • Moriyama M.
        • Sugimachi K.
        Laparoscopy-assisted Billroth I gastrectomy.
        Surg Laparosc Endosc. 1994; 4: 146-148
        • Kim Y.W.
        • Yoon H.M.
        • Eom B.W.
        • Park J.Y.
        History of minimally invasive surgery for gastric cancer in Korea.
        J Gastric Cancer. 2012; 12: 13-17
        • Etoh T.
        • Inomata M.
        • Shiraishi N.
        • Kitano S.
        Minimally invasive approaches for gastric cancer-Japanese experiences.
        J Surg Oncol. 2013; 107: 282-288
        • Vinuela E.F.
        • Gonen M.
        • Brennan M.F.
        • Coit D.G.
        • Strong V.E.
        Laparoscopic versus open distal gastrectomy for gastric cancer: a meta-analysis of randomized controlled trials and high-quality nonrandomized studies.
        Ann Surg. 2012; 255: 446-456
        • Shinohara T.
        • Satoh S.
        • Kanaya S.
        • et al.
        Laparoscopic versus open D2 gastrectomy for advanced gastric cancer: a retrospective cohort study.
        Surg Endosc. 2013; 27: 286-294
        • Hur H.
        • Lee H.Y.
        • Lee H.J.
        • et al.
        Efficacy of laparoscopic subtotal gastrectomy with D2 lymphadenectomy for locally advanced gastric cancer: the protocol of the KLASS-02 multicenter randomized controlled clinical trial.
        BMC Cancer. 2015; 15: 355
        • Inaki N.
        • Etoh T.
        • Ohyama T.
        • et al.
        A multi-institutional, prospective, phase II feasibility study of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for locally advanced gastric cancer (JLSSG0901).
        World J Surg. 2015; 36: 2734-2741
        • Hu Y.
        • Huang C.
        • Sun Y.
        • et al.
        Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial.
        J Clin Oncol. 2016; 34: 1350-1357
        • Shitara K.
        • Chin K.
        • Yoshikawa T.
        • et al.
        Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
        Gastric Cancer. 2017; 20: 175-181
        • Washington K.
        7th edition of the AJCC cancer staging manual: stomach.
        Ann Surg Oncol. 2010; 17: 3077-3079
      1. Japanese classification of gastric carcinoma: 3rd English edition.
        Gastric Cancer. 2011; 14: 101-112
        • Dindo D.
        • Demartines N.
        • Clavien P.A.
        Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.
        Ann Surg. 2004; 240: 205-213
        • Okholm C.
        • Goetze J.P.
        • Svendsen L.B.
        • Achiam M.P.
        Inflammatory response in laparoscopic vs. open surgery for gastric cancer.
        Scand J Gastroenterol. 2014; 49: 1027-1034
        • Hayashi T.
        • Yoshikawa T.
        • Aoyama T.
        • et al.
        Impact of infectious complications on gastric cancer recurrence.
        Gastric Cancer. 2015; 18: 368-374
        • Tokunaga M.
        • Tanizawa Y.
        • Bando E.
        • Kawamura T.
        • Terashima M.
        Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer.
        Ann Surg Oncol. 2013; 20: 1575-1583
        • Aoyama T.
        • Yoshikawa T.
        • Shirai J.
        • et al.
        Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
        Ann Surg Oncol. 2013; 20: 2000-2006
        • Croome K.P.
        • Farnell M.B.
        • Que F.G.
        • et al.
        Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches?.
        Ann Surg. 2014; 260: 633-640
        • Malietzis G.
        • Mughal A.
        • Currie A.C.
        • et al.
        Factors implicated for delay of adjuvant chemotherapy in colorectal cancer: a meta-analysis of observational studies.
        Ann Surg Oncol. 2015; 22: 3793-3802
        • Gantt Jr., G.A.
        • Ashburn J.
        • Kiran R.P.
        • Khorana A.A.
        • Kalady M.F.
        Laparoscopy mitigates adverse oncological effects of delayed adjuvant chemotherapy for colon cancer.
        Surg Endosc. 2015; 29: 493-499
        • Nussbaum D.P.
        • Adam M.A.
        • Youngwirth L.M.
        • et al.
        Minimally invasive pancreaticoduodenectomy does not improve use or time to initiation of adjuvant chemotherapy for patients with pancreatic adenocarcinoma.
        Ann Surg Oncol. 2016; 23: 1026-1033